Jemincare Group of Nanchang has started a China Phase I clinical trial of an anti-SARS-CoV-2 neutralizing antibody. In preclinical studies, JMB2002 effectively neutralized live virus infection of Vero E6 cells and showed potent binding and blocking activity. The company said the candidate is derived from a naive human B cell antibody library of healthy donors, a stable cell line that ensures the product's consistency and stability. In 2018, Jemincare established a Research Institute in Shanghai Zhangjiang Science City . More details.... Share this with colleagues: // //